NCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
Clinical Trials
77 trialsNCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT07460726 2026-03-10
PRIAPUS-PCa
CancerCare Manitoba
Not yet recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT06171269 2026-03-04
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
University of Chicago
Phase NA Recruiting
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT07426055 2026-02-23
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Not yet recruiting
NCT07426094 2026-02-23
PRO-BOOST-N
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Not yet recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT03543189 2026-01-29
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT05477823 2026-01-28
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT02454543 2026-01-12
g-RAMPP
Martini-Klinik am UKE GmbH
Phase NA Active not recruiting
NCT07311915 2026-01-06
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Zhongda Hospital
Phase NA Not yet recruiting
NCT05746806 2025-12-31
HypoFocal SRT
Insel Gruppe AG, University Hospital Bern
Phase NA Active not recruiting
NCT07313241 2025-12-31
(RANGER)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT06150417 2025-11-12
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05628363 2025-11-05
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine
Phase NA Active not recruiting
NCT05100472 2025-11-04
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06244004 2025-10-22
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT07172685 2025-09-15
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT06392295 2025-06-15
OCEAN
University of Miami
Phase 2 Recruiting
NCT05790213 2025-06-12
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
Phase 2 Recruiting
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06992232 2025-05-28
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT06582446 2025-03-11
HypoElect
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06446401 2025-03-04
Lead4Care
Uppsala University
Recruiting
NCT06818682 2025-02-21
RELAX
Tata Memorial Centre
Phase 2 Recruiting
NCT06772441 2025-01-13
HypoPro
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT02303327 2024-12-09
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT03569241 2024-12-09
STORM
University Hospital, Ghent
Phase 2 Active not recruiting
NCT06709326 2024-11-29
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer
Umeå University
Phase NA Recruiting
NCT05404139 2024-11-25
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT01542021 2024-10-03
Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01985828 2024-10-03
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
Wake Forest University Health Sciences
Phase NA Completed
NCT06500247 2024-07-15
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT05352178 2024-07-03
SPARKLE
Universitaire Ziekenhuizen KU Leuven
Phase 3 Recruiting
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT06305832 2024-03-12
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting